Beckley Psytech Ltd, the private, clinical-stage biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing effective and rapid-acting psychedelic medicines, today announced the publication of a new paper in The Journal of Psychopharmacology which demonstrates the safety, tolerability and rapid-acting subjective effects of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT (also known as mebufotenin).
Read morePsychological Flexibility and Psychedelics
In a new study, researchers found that psychological flexibility, several facets of mindfulness, and values-congruent living significantly improved following psilocybin and were maintained through week 16.
Additionally, improvements in psychological flexibility and experiential acceptance were strongly associated with reductions in depression severity following psilocybin.
Keep reading for the full article at Nature.com
Read moreMystical Experiences
Keep reading for an interview with a researcher of mystical experiences.
Read moreThe Science of Death
New research into the dying brain suggests the line between life and death may be less distinct than previously thought.
Read morePsychedelics, Psychosis and Manic Symptoms
In the twin data researchers reviewed, mania was also strongly correlated with a genetic predisposition to schizophrenia and to bipolar I disorder.
In other words, those who experienced manic symptoms after psychedelic use may have been more genetically prone to mental illnesses.
Read moreVideo: The Global Psychedelic Survey, Primary Outcomes
Psilocybin for Anxiety
Also the trial’s rate of full remission, or a full cessation of symptoms, was five times greater than the placebo group, a marked and compelling difference in treatment outcomes.
Read moreThe Benefits of Psilocybin
Small clinical trials have shown that one or two doses of psilocybin, given in a therapeutic setting, can make dramatic and long-lasting changes in people suffering from treatment-resistant major depressive disorder, which typically does not respond to traditional antidepressants.
Click here for the link to this article.
Read moreMDMA, Trauma, Addictions and Psychedelics
Dr. Ben Sessa discusses his latest research here.
Psychedelics, Research and the Brain
VA to Fund Studies on Psychedelics for Mental Health
The Department of Veterans Affairs issued a request for applications (RFA) for proposals from its network of VA researchers (in collaboration with academic institutions) to study the use of certain psychedelic compounds in treating posttraumatic stress disorder (PTSD) and depression.
Read more